CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents.
• Multiple myeloma (MM) is a hematologic malignancy with unmet therapeutic needs.
• Understanding the precise mechanisms of novel HDAC inhibitors is crucial for clinical development.

Purpose of the Study:

• To evaluate the anti-cancer activity of CKD-581 in multiple myeloma (MM).
• To elucidate the pharmacological mechanisms underlying CKD-581's anti-cancer effects.
• To assess the therapeutic potential of CKD-581 in hematologic malignancies.

Main Methods:

• In vitro assessment of HDAC inhibition and cancer cell proliferation.
• Analysis of gene and protein expression changes (DACT3, c-Myc, β-catenin, p53, p21, caspase-3, cyclin D1, CDK4, BCL-2).
• In vivo xenograft studies using MM.1S cells.

Main Results:

• CKD-581 potently inhibited various HDAC isozymes and proliferation of MM and lymphoma cells.
• CKD-581 modulated key signaling molecules including DACT3, c-Myc, β-catenin, and apoptosis-related proteins.
• CKD-581 treatment resulted in significant anti-cancer activity in a preclinical MM xenograft model.

Conclusions:

• CKD-581 exhibits potent anti-cancer activity in hematologic malignancies.
• The mechanism involves the inhibition of the Wnt/β-catenin signaling pathway.
• CKD-581 demonstrates therapeutic potential for the treatment of multiple myeloma.